The t(14;18)(q32;q21) translocation is the most common translocation in B cell malignancies being found in 80% of follicular lymphomas and about 20% of diffuse large B cell lymphomas. Only rare cases of de novo acute B cell lymphoblastic leukemia with t(14;18) have been described. We describe five cases of this entity which appears to have very homogeneous clinical, phenotypic and genotypic features. None of these patients had prior history of follicular lymphoma. The disease was characterized by acute clinical features with nodal and/or extranodal disease, massive bone marrow infiltration and rapid increase of circulating blast cells of mature B cell phenotype. All patients disclosed complex chromosomal and molecular abnormalities involving at least the BCL-2 and c-MYC genes. Furthermore, three patients had evidence of BCL-6 involvement and one patient had a p53 mutation. Despite intensive chemotherapy, including for two patients allogeneic bone marrow transplantation in first complete remission, all patients died within a few months. Neuro-meningeal relapse occurred in three of the five patients in spite of neuro-meningeal prophylaxis. De novo leukemia/lymphoma with t(14;18) is a rare entity with a very poor prognosis. Whether early bone marrow transplant could modify the natural history of the disease remains to be determined. An intensive neuro-meningeal prophylaxis appears to be mandatory in these patients. Leukemia (2000Leukemia ( ) 14, 1960Leukemia ( -1966 
Introduction
The translocation t(14;18)(q32;q21) is the chromosomal hallmark of follicular lymphoma. 1 This lymphoma is generally characterized by an indolent course but it frequently progresses into a more aggressive disease, ranging from diffuse large-cell lymphoma to blastic transformation. 2 During this progression, karyotypic complexity 3 as well as additional molecular defects including p53 mutations 4 and c-MYC oncogene deregulation 5 may occur. About 20% of diffuse large-cell lymphomas show a t(14;18), 3 but only very rare cases of de novo acute lymphoblastic leukemia (ALL) with t(14;18) have been described. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Most of these cases exhibited a pre-B or B cell ALL phenotype, had chromosomal abnormalities involving band 8q24 and/or c-MYC rearrangement and had a very aggressive clinical course. We report five new cases of de novo leukemia/lymphoma with t(14;18) translocation.
Case reports

Patient 1 (UPN 76)
A 50-year-old woman presented in December 1985 with a 10-day history of fatigue, abdominal pain and peripheral edema. Clinical examination showed multiple enlarged lymph nodes and CT scan of the abdomen revealed a large retroperitoneal mass. Laboratory studies showed an hemoglobin level of 10.4 g/dl, a platelet count of 72 × 10 9 /l, and a white blood cell (WBC) count of 8.1 × 10 9 /l with 35% abnormal lymphoid cells. Bone marrow aspirate and trephine biopsy showed a complete replacement of normal bone marrow by abnormal cells. There was no evidence for paratrabecular aggregates typical of follicular lymphoma. Blood, bone marrow and lymph node cells had the same morphology: small size (12 m) with round nuclei, immature chromatin, high nuclear/cytoplasmic ratio, and basophilic cytoplasm ( Figure  1 ). A diagnosis of acute lymphoblastic leukemia was made. The patient died from disease progression 5 days after the onset of combination chemotherapy. Chromosomal and molecular findings in the VAL cell line, grown from bone marrow cells of this patient, have been previously described.
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Patient 2 (UPN 356)
In February 1991, a 44-year-old man presented with a 1-month history of asthenia, anorexia, abdominal pain and weight loss. Clinical examination revealed generalized lymphadenopathy, hepatomegaly and splenomegaly. Laboratory studies showed an hemoglobin level of 11.2 g/dl, a platelet count of 17 × 10 9 /l and a WBC count of 16.8 x 10 9 /l with 12% blast cells. A test for HIV serology was negative. Initial cerebrospinal fluid (CSF) examination was normal. Abdominal CT scan showed a coeliomesenteric mass with hepatomegaly and splenomegaly. Axillary lymph node biopsy showed a diffuse infiltration by monomorphic medium-sized cells with a regular nucleus. Bone marrow was infiltrated with 82% lymphoid cells, about half of them were large cells with scanty basophilic cytoplasm and a nucleus containing one to three
Figure 1
Bone marrow smear in patient 1. 20 Despite CNS prophylaxis, a meningeal relapse occurred after the third course. The patient received salvage chemotherapy with IVAM regimen (ifosfamide 1500 mg/m 2 daily for 5 days + mesna, etoposide 150 mg/m 2 daily for 3 days, cytarabine 100 mg/m 2 daily for 3 days, methotrexate 3 g/m 2 at day 5 with leucovorin rescue) 21 followed by an autologous peripheral blood stem cell transplantation. A partial remission was achieved but the patient died from progressive disease two months after transplantation.
Patient 3 (UPN 459)
In May 1993, a 27-year-old woman presented with progressive muscle weakness. Physical examination showed generalized lymphadenopathy, hepatomegaly, splenomegaly and a skull left parietal mass. Admission laboratory studies showed an hemoglobin level of 8.5 g/dl, the platelet count was 108 × 10 9 /l, and the WBC count was 7.6 × 10 9 /l with 24% blast cells. WBC increased in a few days to a level of 35.8 × 10 9 /l with 80% blasts cells. LDH level was 5017 U/l (normal value Ͻ240 U/l) and ␤2-microglobulin level was 5.3 mg/l (normal value: 0.7-3.4 mg/l). Serologic test for HIV was negative. Chest and abdominal CT scan revealed mediastinal and retroperitoneal lymphadenopathy. CSF examination was normal. Lymph node and skull mass biopsy showed a diffuse infiltration by lymphoma cells with round nucleus usually containing one central nucleolus. Numerous mitoses were seen. The lesion was classified as a diffuse large B cell lymphoma. Bone marrow showed a massive infiltration with extensive necrosis. Three courses of ACVBP (doxorubicin 75 mg/m 2 at day 1, cyclophosphamide 1200 mg/m 2 at day 1, vindesine 2 mg/m 2 at days 1 and 5, bleomycine 10 mg at days 1 and 5, prednisone 60 mg/m 2 from day 1 to day 5 and intrathecal methotrexate 12 mg at day 1) 22 allowed a complete remission. An allogeneic bone marrow transplantation with a sibling donor was attempted on August 1993. The conditioning regimen included chemotherapy (cyclophosphamide 1 g/m 2 for 4 days , cytarabine 150 mg/m 2 for 4 days and etoposide 125 mg/m 2 for 4 days) and a 12 Gy fractionated total body irradiation. Low doses of methotrexate in association with cyclosporine were given as GVHD prophylaxis. Thrombocytopenia and bone marrow necrosis persisted after transplantation. Three months later, the patient died from Pneumocystis carinii and cytomegalovirus interstitial pneumonia without recovery of a normal platelet level.
Patient 4 (UPN 571)
In May 1995, a 38-year-old woman was admitted because of a 7-month history of pain of the right thigh. Radiography of the femur showed a diaphysal osteolytic lesion. Laboratory studies revealed an anemia with an hemoglobin level at 9.6 g/dl and a WBC count at 16.8 × 10 9 /l rapidly increasing to 71.7 × 10 9 /l with 61% abnormal cells. The creatinin level was 486.75 mol/l (normal value: 35-125 mol/l). The physical examination and CT scan revealed right axillary lymphadenopathy, hepatomegaly, splenomegaly and enlarged kidneys.
Leukemia LDH level was 5744 U/l and ␤2-microglobulin level was 10.2 mg/l. A test for HIV antibodies was negative. Initial CSF examination was normal. Lymph node and bone marrow biopsies showed a diffuse infiltration by monomorphic medium-to large-sized cells with a regular nucleus containing several nucleoli in agreement with the diagnosis of diffuse large-cell lymphoma. Blood cells had the same morphology with inconspicuous nucleoli in some cells. After four courses of ACVBP, all physical and laboratory abnormalities improved but the radiography of the femur remained abnormal. As a HLA-identical sibling was available, an allogeneic bone marrow transplantation was planned. Unfortunately, meningeal relapse occurred before BMT and the patient died despite salvage chemotherapy.
Patient 5 (UPN 679)
In February 1997, a 46-year-old woman presented with a 2-month history of night sweats, asthenia and anorexia. Clinical examination revealed generalized lymphadenopathy, hepatomegaly and splenomegaly, ascitis and bilateral pleural effusion. Hemoglobin level was 10 g/dl, platelet count 144 × 10 9 /l, and WBC count 31.8 × 10 9 /l with 25% blast cells. LDH level was 725 U/l, ␤2-microglobulin level was 3.8 mg/l. Initial CSF examination was normal. Serologic test for HIV was negative. Chest CT scan showed mediastinal lymphadenopathy and pleural effusion. Abdominal CT scan revealed a retroperitoneal lymphadenopathy. A nodal axillary biopsy showed a diffuse infiltration by monomorphic medium-sized cells with regular nuclei, numerous mitoses and a few scattered macrophages. The bone marrow was massively infiltrated by the same cells (Figure 2 ) but some nodular areas could be seen which were highlighted by immunochemistry. This features were consistent with Burkitt's lymphoma or 'blastic variant/transformation' of follicular lymphoma. A partial remission was obtained after four courses of ACVBP. 22 The patient underwent allogeneic bone marrow transplantation with a sibling donor. Conditioning regimen consisted of the association of chemotherapy (cyclophosphamide 1 g/m 2 for 4 days, cytarabine 150 mg/m 2 for 4 days and etoposide 125 mg/m 2 for 4 days) and a 12 Gy fractionated total body irradiation. Low doses of methotrexate and cyclosporine were given as GVHD prophylaxis. The patient died 3 months after transplantation from CNS relapse with meningeal involvement.
Figure 2
Bone marrow smear in patient 5.
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Materials and methods
Immunocytology and immunohistochemistry
A panel of monoclonal antibodies was used to screen differentiation antigens on cell suspensions from blood, bone marrow and lymph node by direct immunofluorescence: CD2, CD3, CD4, CD8, CD5, CD10, CD19, CD20, CD37 and surface immunoglobulin. Immunohistochemistry on lymph nodes and bone marrow specimens was performed as possible with anti-CD3, CD20, CD79a, CD5, CD10, MiB1/Ki67, BCL-2 and p53 using an indirect immunoperoxidase or alkaline phosphatase antialkaline phosphatase (APAAP) method.
Cytogenetic analysis
The chromosomal analysis was performed as previously described. 23 
DNA extraction and Southern blot analysis
High molecular weight DNA was extracted by the sarkosylproteinase K-phenol/chloroform method and digested using four restriction enzymes (EcoR1, BamH1, HindIII, XbaI). After digestion, DNA fragments were electrophoresed on 0.8% agarose gels, transferred on to nylon N+ membranes and hybridized according to the recommendations of the suppliers (Amersham, Little Chalfont, UK).
Immunoglobulin heavy chain genes rearrangements were investigated using a Sau3A 2.2 kb JH probe kindly provided by Dr P Guglielmi (INSERM U 108, Paris, France). BCL-2 probes Pfl1 (MBR) and Pfl2 (mcr) were obtained from Dr M 
+i(1)(q10),add(4)(p16),+7,add(9)(q34),add(10) CD20 + (p15),der(11)(q21),−13,t(14;18)(q32;q21), bcl-2
47-48,XX,+add(X)(p12)(q21),add(1)(p33)(q44), add(4)(p16),+add(7)(q31),add(10)(p15), add(11)(q21),add(13)(q34),t(14;18)(q32;q21), del(17)(p13),add (19) Cleary (Stanford University School of Medicine, CA, USA). The two MYC probes used in this study were generous gifts of Dr M Raffeld (NIH, Bethesda, MD, USA). The two BCL-6 probes F370 and F372 have been previously described. 24 
EBV detection
Detection of EBV RNA was performed using fluorescein-conjugated oligonucleotides complementary to portions of the EBV uncoded early RNA transcripts (EBER1/2; Dako, Copenhagen, Denmark), as previously described. 25 
P53 study
P53 mutations occurring in exons 5-8 were screened by denaturating gradient electrophoresis (DGGE) according to Hamelin et al. 26 For patient number 1, DNA was extracted from the VAL cell line. 18, 19 For the three other patients, DNA was extracted from biopsy specimens.
Results
As from January 1985 to December 1999, 143 new cases of adult ALL were karyotyped in our department, the proportion of de novo ALL with t(14;18) could be estimated to 3%.
Immunologic phenotype
The results are summarized in Table 1 . In all five patients, marrow blasts expressed B cell antigens (CD10, CD19, CD20, CD37, FMC7 and surface Ig) with strong surface expression of Ig and lacked expression of T and myeloid differentiation antigens.
Cytogenetics
As shown in Table 1 , the five patients had a complex karyotype. A t(14;18)(q32;q21) was present in all cases. In three patients, this translocation was associated with an involvement of the 8q24 region: a t(8;14)(q24;q32), a t(8;22)(q24;q11) and a complex t(8;14;18)(q24;q32;q21). In addition, the marker chromosome found in patient 4 contained fragments from both chromosomes 7 and 8, and could involve 8q24. The 3q27 region was implicated in three patients, in various translocations: t(3;4)(q27;p13), t(2;3)(p12;q27) and t(3;13)(q27;q14) in patients 1, 4 and 5 respectively. Three patients displayed a 2p12 defect: a duplication, a deletion and a translocation. 13q14 rearrangements could be identified in two patients. A cytogenetic abnormality involving 17p13 could be noted only in patient 3.
DNA analysis
As usual in follicular lymphomas, all patients displayed two rearranged bands upon Southern analysis using a JH probe. BCL-2 rearrangements could be evidenced in patients 1, 2, 3 and 5. The breakpoint of patient 4 could not be detected with Leukemia probes exploring the MBR, mcr and vcr regions. In patients 1,3, 4, 5, MYC exon 1 and exon 3 probes were able to detect a break in the 5Ј part of the gene. Patient 2 had a t(8;22)(q24;q11), that often breaks MYC far from the region that can be explored with these probes. Two of the three patients with 3q27 translocations showed a BCL-6 rearrangement involving the MTC. In patient 1, the second BCL-6 allele was disrupted by a deletion removing 2400 bp in the MTC region. 19 
EBV detection
Detection of EBV virus could be assessed in patients 3, 4 and 5. None of them were positive.
P53 mutation detection
Four patients (patients 1, 3, 4, 5) were tested. A p53 mutation located on codon 176 was detected in patient 4.
Discussion
The presence of a t(14;18) in a case of de novo acute lymphoblastic leukemia (ALL) was first described by Mufti et al 6 15 years ago. Nineteen cases have been subsequently reported (Tables 2 and 3 ). Nine cases had FAB ALL L3 mor- phologic features (8-11, 13, 15, 17) , seven cases were diagnosed as ALL L2 (6, 7, 9, 10, 13, 16) and three were described as high grade NHL with leukemic involvement or ALL with nodal and/or extranodal localizations, as our patients. Immunophenotype study in these cases always revealed the presence of B cell-associated markers as CD10 and CD19 but some cases with a morphologic aspect of ALL L3 lacked cytoplasmic and membranous immunoglobulins. 6, 8, 9, 10, 12 This particular feature underlined by Gluck et al 8 was also found by Thangavelu et al, 9 who suspected a correlation with the presence of a t(8;14) associated with the t(14;18). All our cases expressed surface immunoglobulin with kappa light chains and were CD10 positive, all features consistent with Burkitt's lymphoma/leukemia or diffuse large-cell lymphoma.
All described cases of de novo ALL with t(14;18) had complex chromosomal aberrations. The implication of band 8q24 is the rule, found in 20 of the 24 cases. The frequency of variant Burkitt's translocation t (8;22) 8, 9, 12, 14 in this context is noteworthy 9 but this region could also be implicated in t (8;14) , 6, 7, 9, 10, 11 in t(8;9)(q24;p13) 13, 16 or, as in our patient 1, in complex translocation t(8;14;18)(q24;q32;q21). 15 As in our patient 2, molecular implication of c-MYC could not always be demonstrated, 10, 13 especially in translocations not involving immunoglobulin genes. 13 However, in patients 3 and 4, where no apparent 8q24 abnormality was disclosed, a c-MYC rearrangement could be identified. Sequential emergence of molecular defects have been suspected in these cases, leading to the hypothesis of a multistep process. The first event could be the t(14;18) followed by the occurrence of the MYC rearrangement. 7 This hypothesis has been widely used to explain histologic transformation of follicular lymphoma into pre-B ALL 27, 28 or high grade lymphoma. 29, 30 There is some evidence that it could also be the case in de novo acute ALL involving both genes, 15, 18 even in the absence of a previous phase of follicular lymphoma.
The chromosomal and/or molecular involvement of BCL-6 in three of our patients is noteworthy. The combination of these three chromosomal defects appears to be a very rare event. Two of the previously reported cases were considered as ALL L3 type. 13, 17 The four cases of concurrent alterations at 3q27, 8q24, and 18q21 recently reported by Au et al 31 did not have a leukemic profile but had aggressive B cell lymphoma with disseminated disease and frequent CNS involvement. Molecular clues for triple rearrangement was only obtained in one patient described by these authors and in two of our patients. Even if the t(14;18) is considered as an early event in the development of B cell malignancy, it is difficult in these cases to hypothesize which event is the primary one. The contrast, in these cases, between the very brief course of the disease and the complexity of the rearrangements remains striking.
Clinical presentation and outcome showed many similarities with previously described cases. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Most patients presented with a rapid deterioration of physical conditions with fatigue, fever, night sweat and weight loss. Initial presentation associated massive bone marrow infiltration, nodal and extranodal involvement with frequent soft tissue or bone masses. 6, 8, 9, 14, 16, 17 The clinical course was very aggressive with only one patient reported to have a survival exceeding 1 year. 9 Several patients died before any treatment could be initiated. In patients for whom a complete remission (CR) could be obtained, relapse usually occurred within 6 months.
The frequency of CNS relapse was another characteristic of the disease affecting half of the responding patients. 8, 9, 10, 12, 14 Whereas, in our series, the four patients who attained CR received CNS prophylaxis with intrathecal methotrexate, three of them relapsed at this site. It is unclear whether intensive treatment with stem cell support could be beneficial for these patients. With respect to the very aggressive course of the disease, we decided to propose allogeneic transplantation in first CR in patients 3, 4 and 5. Two of them had a CNS relapse before or after transplantation, the third died from transplantrelated toxicity.
This study confirms that de novo acute leukemia/lymphoma with t(14;18) is a subset of tumor with many morphologic, phenotypic and clinical features of Burkitt's leukemia/ lymphoma. If c-MYC deregulation is the rule, other molecular defects, including BCL-6 rearrangement, are found that could explain the very aggressive clinical course. Regarding the frequency of CNS relapse, an intensive prophylaxis should be proposed for these patients.
